Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-01 + Standard Induction in Newly Diagnosed AML
NCT02873338Phase 2Completed
- Sponsor
- Chimerix Inc.
- Start
- Aug 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dociparstat sodium in acute myeloid leukemia (AML) (3 arms), sponsored by Chimerix Inc. Primary endpoint: Morphologic Complete Remission Rate up to 60 days. Started Aug 2016; status: completed.
02
Drugs
dociparstat sodium
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02873338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873338.